Supplementary Figure S5 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
Key Points
Low ctDNA tumor fraction indicates potential for long-term clinical benefit during treatment with immune checkpoint inhibitors.
Patients with tumor fraction values below limit of quantification (LOQ) at both timepoints exhibited better outcomes.
The study employed a real-world cohort, providing insights into the effectiveness of immune therapies across diverse cancer types.
This analysis emphasizes the importance of tumor fraction monitoring in clinical settings, guiding personalized treatment options.
Abstract
Real-world outcomes of patients with TF below LOQ at both timepoints
Supplementary Figure S5 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study | Synapse